Skip to main content

Gemcitabine Disease Interactions

There are 10 disease interactions with gemcitabine.

Major

Antineoplastics (applies to gemcitabine) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories PROD (2002):
  2. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb PROD (2001):
  3. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb PROD (2001):
  4. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation PROD (2001):
  5. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb PROD (2001):
  6. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation) PROD (2001):
  8. "Product Information. Fludara (fludarabine)." Berlex Laboratories PROD (2001):
  9. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):
  10. "Product Information. Matulane (procarbazine)." Roche Laboratories PROD (2001):
  11. "Product Information. DTIC-Dome (dacarbazine)." Bayer PROD (2001):
  12. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn PROD (2001):
  13. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc PROD (2001):
  14. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
  15. "Product Information. Hycamtin (topotecan)." SmithKline Beecham PROD (2001):
  16. "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer PROD (2001):
  17. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb PROD (2001):
  18. "Product Information. Nipent (pentostatin)." Hospira Inc PROD (2001):
  19. "Product Information. Tabloid (thioguanine)." Prasco Laboratories PROD (2001):
  20. "Product Information. Xeloda (capecitabine)." Roche Laboratories PROD (2001):
  21. "Product Information. Alkeran (melphalan)." Glaxo Wellcome (2022):
  22. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome PROD (2001):
  23. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  24. "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc PROD (2001):
  25. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn PROD (2001):
  26. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation PROD (2001):
  27. "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
  28. "Product Information. Halaven (eribulin)." Eisai Inc (2010):
  29. "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc. (2021):
View all 29 references
Major

Gemcitabine (applies to gemcitabine) cardiovascular dysfunction

Major Potential Hazard, Low plausibility. Applicable conditions: Myocardial Infarction, Arrhythmias, Hypertension

Cardiovascular events such as myocardial infarction, arrhythmia, and hypertension have been reported during gemcitabine therapy. Therapy with gemcitabine should be administered cautiously in patients with cardiovascular dysfunction.

References

  1. Carmichael J, Philip P, Rea D, Kerr H, Walling J, Harris AL, Possinger K "GEMCITABINE: AN ACTIVE DRUG IN ADVANCED BREAST CANCER. RESULTS OF A PHASE II STUDY (MEETING ABSTRACT)." Proc Annu Meet Am Soc Clin Oncol 11 (1992): a1361992
  2. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
Major

Gemcitabine (applies to gemcitabine) hemolytic uremic syndrome

Major Potential Hazard, Low plausibility. Applicable conditions: Renal Dysfunction

Hemolytic uremic syndrome (HUS), including fatalities from renal failure or the requirement for dialysis can occur in patients treated with gemcitabine. Renal function should be assessed prior to treatment initiation. Gemcitabine should be permanently discontinued in patients with HUS or severe renal impairment. Renal failure may not be reversible even with discontinuation of therapy.

References

  1. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
Major

Gemcitabine (applies to gemcitabine) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Gemcitabine induces dose-related myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported during gemcitabine therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy should be administered cautiously and dosage modification considered in patients with bone marrow suppression. Close clinical monitory of hematopoietic function is recommended.

References

  1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA "Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study." J Clin Oncol 12 (1994): 1535-40
  2. Guchelaar HJ, Richel DJ, Vanknapen A "Clinical, toxicological and pharmacological aspects of gemcitabine." Cancer Treat Rev 22 (1996): 15-31
  3. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
Moderate

Gemcitabine (applies to gemcitabine) cerebrovascular disease

Moderate Potential Hazard, Low plausibility. Applicable conditions: Cerebral Vascular Disorder

Cerebrovascular accidents have been reported during gemcitabine therapy. Therapy with gemcitabine should be administered cautiously in patients with known cerebrovascular disease.

References

  1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA "Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study." J Clin Oncol 12 (1994): 1535-40
  2. Guchelaar HJ, Richel DJ, Vanknapen A "Clinical, toxicological and pharmacological aspects of gemcitabine." Cancer Treat Rev 22 (1996): 15-31
  3. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
Moderate

Gemcitabine (applies to gemcitabine) edema

Moderate Potential Hazard, High plausibility. Applicable conditions: Fluid Retention

Edema has been reported frequently during gemcitabine therapy. Therapy with gemcitabine should be administered cautiously in patients adversely affected by fluid retention.

References

  1. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
Moderate

Gemcitabine (applies to gemcitabine) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Drug induced liver injury, including liver failure and death, has been reported in patients receiving gemcitabine for injection alone or in combination with other hepatotoxic drugs. Administration of gemcitabine in patients with concurrent liver metastases or preexisting medical history of hepatitis, alcoholism, or liver cirrhosis can lead to exacerbation of any underlying hepatic insufficiency. Hepatic function should be assessed prior to initiation of therapy and during treatment. The manufacturers state that no clinical studies have been conducted with gemcitabine in patients with decreased hepatic function.

References

  1. Guchelaar HJ, Richel DJ, Vanknapen A "Clinical, toxicological and pharmacological aspects of gemcitabine." Cancer Treat Rev 22 (1996): 15-31
  2. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
Moderate

Gemcitabine (applies to gemcitabine) paresthesia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Peripheral Neuropathy

Mild paresthesias and rare severe paresthesias have been reported during gemcitabine therapy. Therapy with gemcitabine should be administered cautiously in patients with or predisposed to neurological dysfunction.

References

  1. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
Moderate

Gemcitabine (applies to gemcitabine) pulmonary dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

Pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS) has been reported with the use of gemcitabine. In some cases, these pulmonary events can lead to fatal respiratory failure despite treatment discontinuation. Caution is advised if using in patients with history of pulmonary disease. Continuous monitoring of pulmonary function is advised.

References

  1. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
Moderate

Gemcitabine (applies to gemcitabine) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

No clinical studies have been conducted with gemcitabine in patients with decreased renal function. Caution is advised if used in these patients.

References

  1. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):

Gemcitabine drug interactions

There are 271 drug interactions with gemcitabine.

Gemcitabine alcohol/food interactions

There is 1 alcohol/food interaction with gemcitabine.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.